First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours
Zaihui Zhang, Donna Morrison, Liang Lu, Madhu Singh, Jun Yan, Natasha Leighl, Scott A Laurie, Sebastien Hotte, Serge Mordon · 2025
Read First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours by Zaihui Zhang, Donna Morrison, Liang Lu, Madhu Singh, Jun Yan, Natasha Leighl, Scott A Laurie, Sebastien Hotte, Serge Mordon (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12736120.txt.
Description
Zaihui Zhang and co-authors run the first human trial of an AXL-blocking cancer drug, SLC-391, in a 2025 study. The AXL receptor helps tumors grow, spread, dodge immunity, and resist therapy, making it an inviting target. The oral drug had already shown punch in lab models.
Thirty-five patients with advanced solid tumors took rising daily or twice-daily doses in three-week cycles. The drug was generally well tolerated, and no maximum tolerated dose was reached. A few severe side effects clustered at the highest doses. Blood levels rose with dose and steadied by the third week. Twelve patients held stable disease, some for nearly a year. A mid-range twice-daily dose looked cleanest for further trials.
Catalog record
| CREATOR | Zaihui Zhang, Donna Morrison, Liang Lu, Madhu Singh, Jun Yan, Natasha Leighl, Scott A Laurie, Sebastien Hotte, Serge Mordon |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |